Endocrinology Research and Practice
Original Article

Parathormone-Related Peptide Is Not Associated with Bone Mineral Density in Eugonadal Prolactinoma


Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Turkey


Endocrinology and Metabolic Diseases Subdivision,Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Turkey

Endocrinol Res Pract 2023; 27: 158-163
DOI: 10.5152/erp.2023.23223
Read: 304 Downloads: 110 Published: 01 July 2023

Objective: One of many theories for the cause of osteoporosis in prolactinoma is the increased level of the parathyroid hormone-related peptide. We aimed to assess the parathyroid hormone-related pep- tide levels and its potential effects on bone mineral density in patients with eugonadal prolactinoma.

Methods: We enrolled 29 eugonadal prolactinoma patients and 31 controls. Serum prolactin, thyroid function tests, calcium, phosphorus, albumin, gonadal steroids, parathyroid hormone, 25-OH vita- min D, alkaline phosphatase, 24-hour urine calcium, parathyroid hormone-related peptide, and bone mineral density were measured.

Results: No statistically significant difference was observed in parathyroid hormone-related peptide levels between the prolactinoma and the control groups (P = .288). The parathyroid hormone-related peptide levels were significantly higher in men in both groups (P < .05). No relationship was observed between the parathyroid hormone-related peptide levels and bone mineral density in g/cm2 for lum- bar vertebrae, femur, and radius (P > .05). Although there was also no significant correlation between parathyroid hormone-related peptide and Z scores of lumbar vertebrae and femur (P > .05), Z scores of radius were significantly correlated with parathyroid hormone-related peptide (P = .001, r = -0.575).

Conclusion: To the best of our knowledge, contrary to hypotheses that the elevated level of para- thyroid hormone-related peptide may be one of the factors contributing to osteoporosis in prolac- tinoma patients, this is the first study revealing that parathyroid hormone-related peptide has no significant impact on osteoporosis in eugonadal prolactinoma patients. Furthermore, this is the first study to demonstrate gender differences in physiological parathyroid hormone-related peptide lev- els. However, additional studies with large samples are required to confirm these findings.

Cite this article as: Okyar Baş A, Cinel M, Demir Ö. Parathormone-related peptide is not associated with bone mineral density in eugonadal prolactinoma. Endocrinol Res Pract. 2023;27(3):158-163.

EISSN 2822-6135